GSK bolsters vaccine business with Merck cast-off

GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.

GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.

Okairos' founders, Riccardo Cortese and his team, were also the founders of Istituto di Ricerche di Biologia Molecolare (IRBM), which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category